预约演示
更新于：2026-03-10
Empagliflozin
恩格列净
更新于：2026-03-10
概要
基本信息
药物类型 小分子化药 |
别名 Empagliflozin (JAN/USAN/INN)、Oboravo、依帕列净 + [10] |
靶点 |
作用方式 抑制剂 |
作用机制 SGLT2抑制剂(钠-葡萄糖协同转运蛋白-2抑制剂) |
在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (美国)、突破性疗法 (美国)、优先审评 (中国)、快速通道 (美国) |
登录后查看时间轴
结构/序列
分子式C23H27ClO7 |
InChIKeyOBWASQILIWPZMG-QZMOQZSNSA-N |
CAS号864070-44-0 |
关联
815
项与 恩格列净 相关的临床试验NCT07044700
Non-interventional Study of the Effectiveness and Safety of Jardiance in Patients With Heart Failure (HF) of Reduced Ejection Fraction (HFrEF) Compared to Guideline-recommended Non-SGLT2i Therapy Regimens in China: A Sub-study of the Postmarketing Study of Jardiance Among Patients With Heart Failure in China
NCT03867487
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
TCTR20251107001
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Empagliflozin Film-Coated Tablets 25 mg relative to JARDIANCE (Empagliflozin Film-Coated Tablets 25 mg) in healthy Thai volunteers under fasting condition
100 项与 恩格列净 相关的临床结果
登录后查看更多信息
100 项与 恩格列净 相关的转化医学
登录后查看更多信息
100 项与 恩格列净 相关的专利（医药）
登录后查看更多信息
3,016
项与 恩格列净 相关的文献（医药）2026-06-01International journal of cardiology. Cardiovascular risk and prevention
Renal and cardiovascular effects of SGLT2 inhibitors among hypertensive patients with chronic kidney disease: A systematic review and meta-analysis
Review
作者: Danny, Siska Suridanda ; Kuncoro, Brm Ario Suryo ; Kosen, Yosua Darmadi ; Amalia, Fauqi ; Pintaningrum, Yusra ; Dharma, Ahmad Surya ; Javier, R Mohamad ; Faizin, Iqbal ; Fiohana, Puput ; Nurpradika, Brianka Yudha ; Firasghani, Muhammad Almy ; Kurniawan, Kristian ; Puspitasari, Renny Anggraeni ; Andiani ; Samudra, Dian
Background:
Chronic kidney disease (CKD) is frequently complicated by hypertension, a dual contributor to disease progression and cardiovascular risk. Despite standard therapy with renin-angiotensin-aldosterone system inhibitors, residual risk remains high. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a novel therapy with proven renal and cardiovascular benefits, but their effects in hypertensive CKD patients remain less well defined.
Methods:
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) that evaluated SGLT2 inhibitors in CKD patients with baseline systolic blood pressure ≥140 mmHg or renovascular disease. PubMed, Embase, and Cochrane Library were searched from inception to August 2024. Eligible RCTs compared an SGLT2 inhibitor versus placebo and reported outcomes in hypertensive subgroups. Primary outcome was a composite of kidney failure, sustained decline in estimated glomerular filtration rate (eGFR ≥40-50 %), or cardiovascular death. Secondary outcomes included kidney-specific endpoints, cardiovascular composite outcomes, and serious adverse events (SAEs). Pooled odds ratios (ORs) were calculated using random-effects models.
Results:
Three RCTs were included: CREDENCE (canagliflozin), DAPA-CKD (dapagliflozin), and EMPA-KIDNEY (empagliflozin), encompassing 5436 hypertensive participants. For the primary outcome, SGLT2 inhibitors reduced risk compared with placebo (OR 0.76, 95 % CI 0.65-0.88). Kidney outcomes showed consistent benefit (OR 0.70, 95 % CI 0.58-0.85). Cardiovascular events were modestly reduced (OR 0.79, 95 % CI 0.64-0.97). SAEs were slightly lower with SGLT2 inhibitors (OR 0.85, 95 % CI 0.74-0.96). Overall certainty of evidence was graded as moderate.
Conclusions:
Among hypertensive patients with CKD, SGLT2 inhibitors significantly reduce renal disease progression and cardiovascular events while maintaining favorable safety. These findings support their integration into standard therapy for this high-risk population.
2026-06-01International journal of cardiology. Cardiovascular risk and prevention
Dose-dependent effects of SGLT2 inhibitors on circadian blood pressure in hypertensive patients with diabetes: A systematic review and Bayesian network meta-analysis
Review
作者: Ebrahimi, Elham ; Roozbehi, Khatere ; Hashempoor, Anahita ; Chichagi, Fatemeh ; Semirani-Nezhad, Davood ; Kuno, Toshiki ; Salehi, Keyvan ; Sabri, Mahshad ; Hosseini, Kaveh ; Shamshiri, Sima ; Moradi, Ali ; Azardar, Tara ; Askari, Mani Khorsand ; Moghadam, Arman Soltani
Objective:
The impact of dose variation of Sodium-glucose co-transporter 2 (SGLT2) inhibitors in reducing blood pressure (BP) in patients with diabetes and hypertension remains unclear.
Methods:
A systematic search up to December 29, 2024 identified randomized trials reporting SGLT2 inhibitor effects on 24-h, daytime, nighttime, and office BP, along with hypoglycemia, urinary tract infections, and volume depletion. Continuous outcomes were synthesized as mean differences and safety outcomes as odds ratios within a Bayesian random-effects network meta-analysis. Dose-response patterns were examined using Bayesian meta-regression (ΔDIC), and treatment rankings were derived using SUCRA.
Results:
Nine RCTs involving 9093 participants were included. SGLT2 inhibitors produced modest reductions across 24-h, daytime, nighttime, and office BP, with the largest numerical effect for empagliflozin 25 mg (SBP -5.93 mm Hg), but no credibly significant differences among agents in head-to-head comparisons. Safety outcomes showed no credibly significant excess risk for hypoglycemia, UTI, or volume depletion, with overall event rates low. Bayesian meta-regression yielded ΔDIC values near zero, indicating no detectable dose-response pattern for either blood pressure or safety outcomes.
Conclusion:
SGLT2 inhibitors produced modest and consistent reductions in BP, with no evidence of dose-dependence or meaningful differences among agents. Safety events were not credibly increased. These findings support their use as adjunctive therapy in patients with diabetes and hypertension.
2026-05-01METABOLISM-CLINICAL AND EXPERIMENTAL
The early metabolic cardiac targets of empagliflozin during the development of heart failure, independent of SGLT2 inhibition
Article
作者: Lykidou, Myrto ; van Goor, Femke K J ; Guan, Yingyin ; van Weeghel, Michel ; Zuurbier, Coert J ; Chen, Sha ; Hollmann, Markus W ; Schomakers, Bauke V ; Creemers, Esther E ; Bakker, Diane ; Wang, Qian ; Hu, Xin ; van der Made, Inge ; Weber, Nina C ; Coronel, Ruben ; Pieper, Michael P ; Tebbens, Anna M
BACKGROUND & PURPOSE:
Cardiac metabolic changes are known early drivers of heart failure (HF). Recent preclinical research showed that protection against HF by sodium glucose transporter 2 inhibitors (SGLT2i) is independent of SGLT2 inhibition. Here, we unravel the SGLT2-independent metabolic effects of SGLT2i during early HF, to shed light on the early cardiac metabolic mechanisms through which SGLT2i may confer protection against HF.
METHODS:
Short-term HF was induced through transverse aortic constriction (TAC) and deoxycorticosterone (DOCA) administration in WT and SGLT2 KO mice, in the presence or absence of Empagliflozin (EMPA). Ten days post-surgery, following in vivo echocardiography, hearts were Langendorff-perfused. The SGLT2-independent metabolic effects of EMPA were determined by: 1) performing stable isotope tracer analysis for 13C-glucose to asses relative glucose contribution to metabolic pathways via fluxomics (13C-glucose perfusion), 2) quantifying metabolic intermediates using metabolomics (LC/MS), 3) evaluating metabolic regulators through Western blot analysis, and 4) analyzing gene expression of metabolic pathways via RNA sequencing.
RESULTS:
Independent of SGLT2 (i.e., being present in both genotypes), TAC/DOCA resulted in in vivo HF (systolic and diastolic dysfunction) that was prevented by EMPA. The early SGLT2-independent cardiac metabolic properties showed: 1) HF hearts used relatively less glucose for energy production through glycolysis and TCA cycle, with more glucose being diverted toward synthesis of glutamine. In contrast, EMPA enhanced glucose labeling of the distal part of glycolysis without affecting relative glucose contribution to acetyl CoA or TCA intermediates, 2) HF led to increased metabolic intermediates (malate, aspartate, 2-hydroxyglutarate) that are known to drive pathology, whereas EMPA reduced pathology-causing metabolic intermediates (malate, glucose-6-P), together with increased lactate release and ATP content, 3) EMPA increased the metabolic regulator SIRT3 and the insulin-sensitive glucose transporter (GLUT4) without affecting AMPK, and 4) HF decreased fatty acid metabolism gene expression, whereas EMPA increased multiple mitochondrial metabolic pathways (TCA cycle, branched-chained amino acid, fatty acid, mitochondrial respiratory chain complexes), possibly through increased ERRα signaling.
CONCLUSION:
The early, SGLT2-independent, metabolic mechanism marking HF protection by SGLT2i entail 1) decreases in metabolic intermediates that drive hypertrophy (G6P, malate), 2) boosting glycolysis (GLUT4, distal part glycolysis, lactate release) without shifting glucose/fatty acid oxidation ratio, and 3) activating ERRα/SIRT3 pathway associated with increased gene expression of mitochondrial energy pathways and improved cardiac ATP levels.
100 项与 恩格列净 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心血管疾病 | 中国 | 2023-05-26 | |
| 心血管疾病 | 中国 | 2023-05-26 | |
| 射血分数保留型心力衰竭 | 中国 | 2022-08-30 | |
| 射血分数保留型心力衰竭 | 中国 | 2022-08-30 | |
| 射血分数降低的心力衰竭 | 中国 | 2022-06-10 | |
| 射血分数降低的心力衰竭 | 中国 | 2022-06-10 | |
| 慢性心力衰竭 | 欧盟 | 2014-05-22 | |
| 慢性心力衰竭 | 冰岛 | 2014-05-22 | |
| 慢性心力衰竭 | 列支敦士登 | 2014-05-22 | |
| 慢性心力衰竭 | 挪威 | 2014-05-22 | |
| 慢性肾病 | 澳大利亚 | 2014-04-30 | |
| 2型糖尿病 | 澳大利亚 | 2014-04-30 | |
| 心脏衰竭 | 澳大利亚 | 2014-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 先天性心脏缺损 | 临床3期 | 加拿大 | 2025-05-01 | |
| 肾性糖尿 | 临床3期 | 埃及 | 2023-05-25 | |
| 精神分裂症 | 临床3期 | 埃及 | 2023-05-25 | |
| 代谢功能障碍相关脂肪性肝炎 | 临床3期 | 埃及 | 2022-11-01 | |
| 低血糖 | 临床3期 | 瑞士 | 2022-03-11 | |
| 胎儿水肿 | 临床3期 | 意大利 | 2020-03-05 | |
| 脂肪萎缩性糖尿病 | 临床3期 | 日本 | 2019-09-01 | |
| 胰岛素抵抗 | 临床3期 | 日本 | 2019-09-01 | |
| 自身免疫性胰岛素受体病 | 临床3期 | 日本 | 2019-09-01 | |
| 妊娠期糖尿病 | 临床3期 | 加拿大 | 2018-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 190 | 衊艱齋遞淵築觸餘積網(繭觸膚鹽鹹網鏇鹹願鏇) = No significant treatment effect was observed in the middle or highest tertiles of RVFWS. 夢夢選鹽衊製餘遞衊糧 (膚壓夢艱憲顧蓋簾鹹壓 ) | 不佳 | 2026-01-08 | |||
临床3期 | 6,609 | 壓範簾餘繭窪壓憲糧築(獵夢艱淵鑰膚繭獵廠積) = Mean cumulative incidence of ACH in empagliflozin and placebo groups diverged shortly after randomization and separated further over time. 廠夢選鏇顧範糧簾鹽餘 (積艱襯鏇鏇遞觸壓構築 ) 更多 | 积极 | 2025-12-01 | |||
Placebo | |||||||
临床4期 | 80 | 壓構蓋範廠鏇範鬱壓衊(積鬱顧簾齋範製窪艱蓋) = 鹽鹽衊襯淵醖顧窪顧壓 糧蓋積鹹膚網鹽夢膚鏇 (選網廠憲鑰繭顧醖衊衊, 2.0) 更多 | 积极 | 2025-11-19 | |||
壓構蓋範廠鏇範鬱壓衊(積鬱顧簾齋範製窪艱蓋) = 範廠範鬱淵淵餘鏇襯壓 糧蓋積鹹膚網鹽夢膚鏇 (選網廠憲鑰繭顧醖衊衊, 3.2) 更多 | |||||||
N/A | 798 | 網簾範獵襯獵艱鏇築膚(壓鑰構顧窪積鏇襯醖選) = 簾顧顧築構顧壓製醖淵 鑰鏇壓壓觸鏇鹽壓願衊 (鏇壓齋壓網壓醖製觸艱 ) | 积极 | 2025-11-07 | |||
網簾範獵襯獵艱鏇築膚(壓鑰構顧窪積鏇襯醖選) = 鑰顧願製衊製鹽積鬱鏇 鑰鏇壓壓觸鏇鹽壓願衊 (鏇壓齋壓網壓醖製觸艱 ) | |||||||
临床3期 | 779 | 鑰鏇蓋鏇鑰壓襯膚網選(鏇壓膚願獵觸鹽鑰廠範) = 獵遞壓夢憲憲網醖襯鏇 積鏇製繭遞鏇窪夢襯餘 (壓襯獵鑰鏇蓋艱範製蓋 ) | 不佳 | 2025-11-01 | |||
鑰鏇蓋鏇鑰壓襯膚網選(鏇壓膚願獵觸鹽鑰廠範) = 餘淵獵憲鏇製壓簾構糧 積鏇製繭遞鏇窪夢襯餘 (壓襯獵鑰鏇蓋艱範製蓋 ) | |||||||
临床2期 | 47 | Aptar Pharma CPS Intranasal Delivery Device+Insulin (Humulin® R U-100) (Intranasal Insulin and Empagliflozin Placebo) | 築鹹鹽餘繭鹽積願願襯 = 顧構壓鑰醖蓋鏇繭繭鬱 願願蓋鬱網齋膚網構膚 (鬱廠艱顧製獵廠齋壓餘, 窪簾淵鑰壓獵糧簾鬱鹹 ~ 蓋憲壓簾顧顧遞鑰構襯) 更多 | - | 2025-10-21 | ||
Aptar Pharma CPS Intranasal Delivery Device+Empagliflozin 10 MG (Empagliflozin and Intranasal Insulin Placebo) | 築鹹鹽餘繭鹽積願願襯 = 範齋襯夢鬱願鹽蓋觸觸 願願蓋鬱網齋膚網構膚 (鬱廠艱顧製獵廠齋壓餘, 範鑰鑰鬱築獵衊淵積願 ~ 艱鬱顧糧網膚衊鏇醖願) 更多 | ||||||
临床2期 | 91 | 憲鬱範衊襯淵鬱願蓋夢(淵鹹襯廠廠繭顧夢糧觸): P-Value = 0.43 更多 | 不佳 | 2025-09-18 | |||
Placebo | |||||||
临床3期 | - | 818 | 鹽願獵醖窪積艱糧鏇範(積築鹽鏇糧鏇獵繭夢鹽) = 範獵膚齋簾鏇獵積鏇顧 鏇壓積積鹽顧範窪艱衊 (醖夢襯鑰醖襯廠餘遞範 ) 更多 | 积极 | 2025-08-31 | ||
临床3期 | 6,609 | 醖遞構艱獵蓋窪廠夢選(襯網淵憲鏇遞顧窪鏇醖) = 夢構選鬱醖壓選鏇構觸 築鹽淵壓築蓋壓蓋壓夢 (夢鏇鑰衊選築膚膚願繭 ) | 积极 | 2025-07-01 | |||
N/A | 心脏衰竭 type 2 diabetes | - | 膚夢夢膚鹽衊簾願鬱範(築糧鏇餘製鑰顧壓齋壓) = 鹽醖積積襯鑰艱餘構襯 顧繭選獵獵製餘獵壓醖 (遞鏇糧膚窪鏇餘鏇齋糧 ) 更多 | 积极 | 2025-06-18 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用